KB-1285

Atezolizumab

Background

Atezolizumab, a high affinity-specific humanized IgG1 antibody against PD-L1, is FDA approved for use in metastatic NSCLC after disease progression on platinum-containing chemotherapy. Atezolizumab was first evaluated in a phase I study that included patients with advanced incurable cancer, including NSCLC, melanoma, renal cell carcinoma, colorectal cancer, gastric cancer, and head and neck squamous cell carcinoma.

Specifications

Catalog Number:
KB-1285
Cell Line Name:
Atezolizumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
PDL1
Species Reactivity:
Human
Application:
ELISA | FACS | Blocking assay | Function Assay | KD
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA | FACS | Blocking assay | Function Assay | KD

References

1.Cortinovis D, von Pawel J, Syrigos K, et al. Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: safety population analyses from the Ph III study OAK. Ann Oncol 2017;28:v468–96. 2.Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837–46.
Please enable JavaScript in your browser to complete this form.